Supplementary Tables

Table S1. Clinicopathological characteristics of patients

Characteristics	No. （%）
Gender	
Male	48 （37.5）
Female	80 （62.5）
Age(years)	
<60	65 （50.78）
>=60	63 （49.22）
Smoke	
Yes	52 （40.63）
NO	76 （59.38）
T classification	
T1	75 （58.59）
T2	49 （38.28）
T3	2 （1.56）
T4	2 （1.56）
N classification	
N0	80 （62.50）
N1	7 （5.47）
N2	41 （32.03）
M classification	
M0	127 （99.22）
M1	1 （0.78）
Clinical stage	
Ⅰ	75 （58.59）
Ⅱ	11 （8.59）
Ⅲ	41 （32.03）
ⅠⅤ	1 （0.78）
Patient survival	
Alive	99 （77.34）
Deceased	29 （22.66）
Expression of miR-135b	
Low expression	61 （47.66）
High expression	67 （52.34）

Table S2. DNA sequences of qRT-PCR primers

Primer name	Sequence
GAPDH_Fwd	GAAGGTGAAGGTCGGAGTCA
GAPDH_Rev	TTGAGGTCAATGAAGGGGTC
Bcl-2_Fwd	GACTGAGTACCTGAACCGGC
Bcl-2_Rev	CAGCCAGGAGAAATCAAACAG
Bcl-xL_Fwd	GTATTGGTGAGTCGGATCGC
Bcl-xL-Rev	TGCTGCATTGTTCCCATAGA
MMP9_Fwd	GGGACGCAGACATCGTCATC
MMP9_Rev	TCGTCATCGTCGAAATGGGC
A20_Fwd	GCGTTCAGGACACAGACTTG
A20_Rev	TTCATCATTCCAGTTCCGAGTATC
NFKBIA_Fwd	GTCAAGGAGCTGCAGGAGAT
NFKBIA_Rev	TCATGGATGATGGCCAAGT
VEGFC_Fwd	GTGTCCAGTGTAGATGAACTC
VEGFC_Rev	ATCTGTAGACGGACACACATG
IL-1β_Fwd	AGCTGATGGCCCTAAACAGA
IL-1β_Rev	CCTGAAGCCCTTGCTGTAGT
IL-6_Fwd	AGTGAGGAACAAGCCAGAGC
IL-6_Rev	CATTTGTGGTTGGGTCAGG
IL-8_Fwd	CGGAAGGAACCATCTCACTG
IL-8_Rev	AGCACTCCTTGGCAAAACTG

Table S3. Correlation between the clinicopathological features and expression of miR-135b

Characteristics	miR-135bexpression		χ^2 Test P-Value	Fisher Exact Test P-Value
	Low	High		
Gender				
Male	24	24	0.717	-
Female	37	43		
Age(years)				
<60	26	39	0.111	-
>=60	35	28		
Smoke				
Yes	28	24	0.041	
NO	33	43		
T classification				
T1	40	35		
T2	19	30	-	0.438
T3	1	1		
T4	1	1		
N classification				
N0	34	46		
N1	5	2	-	0.244
N2	22	19		
M classification				
M0	61	66	-	1.000
M1	0	1		
Clinical stage				
I	32	43		
II	8	3		
III	21	20	-	0.165
IV	0	1		

Supplementary Figure Legends

Figure S1 Verification of miR-135b stably up- or downregulated NSCLC cell lines. (**A**) Real-time PCR measuring miR-135b level in miR-135 overexpressing cells. (**B**) Real-time PCR measuring miR-135b level in miR-135 inhibiting cells. Error bars represent the mean $\pm$ SD. **, $p<0.01$; ***, $p<0.001$, two-tailed, unpaired t-test.

Figure S2 miR-135b promotes cell migration, invasion, anti-apoptosis and angiogenesis in NSCLC *in vitro*. (**A, B**) Quantification of migrated (**A**) and invaded (**B**) cells in the indicated cell lines, related to Figure 3A-B. (**C**) Quantification of TUNEL positive cells in the indicated cell lines, related to Figure 3C. (**D**) Representative images of cells treated with cisplatin (DDP) taken under a bright field microscope. Scale bars, 50μm. (**E**) Western blotting analysis of the protein levels of PARP and cleaved-PARP in the indicated cells. β-Tubulin served as a loading control. (**F**) Quantification of migrated HUVECs, related to Figure 3D. Error bars represent the mean $\pm$ SD. *, $p<0.05$; **, $p<0.01$; ***, $p<0.001$, two-tailed, unpaired t-test.

Figure S3 miR-135b promotes nuclear translocation of NF-κB/p65. Representative images (A) and quantification (B) of p65 nuclear positive cells in indicated cells, related to Figure 4G. Scale bars, 20μm. Error bars represent the mean $\pm$ SD. *, $p<0.05$; **, $p<0.01$; ***, $p<0.001$, two-tailed, unpaired t-test.

Figure S4 Rescuing the expression of CYLD reversed the effects of miR-135b on cellular behaviors. (**A**) Quantification of EdU positive cells in indicated cell lines, related to Figure 6B. (**B, C**) Quantification of migrated (**B**) and invaded (**C**) cells in indicated cell lines, related to Figure 6C-D. (**D**) Quantification of TUNEL positive cells in indicated cell lines, related Figure 6E. Error bars represent the mean $\pm$ SD. *, $p<0.05$; **, $p<0.01$; ***, $p<0.001$, two-tailed, unpaired t-test.